Skip to main content

Education/ACR/EULAR

      In this week's podcast, Drs. Artie Kavanaugh and Jack Cush present highlights from the virtual EULAR2020 meeting held June 3-6, 2020. Featured reports include the SELECT-CHOICE study, the EXCEED trial, Avacopan in AAV, BeST mortality outcomes, BLISS-LN study, biosimilars and tofa in systemic sclerosis.
      These were my top abstracts from Thursday, 4th of June at EULAR 2020:
      Gout Review from EULAR2020

      Dr. Olga Petryna reviews highlights from the virtual EULAR 2020 meeting June 3-6, 2020

      These were my top abstracts from Thursday, 4th of June at EULAR 2020:
      For a disease that has been recognized since the days of Hippocrates, we are finally making some progress towards understanding systemic lupus erythematosus (SLE) and how to tame the wolf.  Listed below are the top 5 studies and their summaries presented at the recent EULAR e-Congress conference streamed from Germany that I found impactful:
      Flares in ANCA-associated vasculitis are difficult to predict, but serum calprotectin may help predict relapse and renal failure, according to data presented at the EULAR 2020 virtual meeting this week.
      Every time a big scientific meeting ends I ask myself a question: how is it going to affect the way I treat my patients? This year the question pertains to management of axial spondyloarthropathies and psoriatic arthritis. Actually, this question has been brewing for several years now, but only now we get more data to form more or less feasible answer. So let’s see what EULAR 2020 has to offer.
      Virtual Meeting Review - EULAR 2020

      Drs. Kathryn Dao, Rachel Tate and Jack Cush discuss virtual meetings, EULAR2020, pluses, minuses and future proposals.

      Updated EULAR Recommendations for RA Management

      Dr. Kathryn Dao from EULAR2020 Virtual Conference

      Easier Early Arthritis

      Dr. David Liew from EULAR2020 Virtual Conference

      Early Patient Referrals

      Preclinical RA patients

      RT @DrPetryna: #EULAR2020 #op0054 DISCOVER 1&2 rct results for Guselkumab in PsA w/ sacroiliitis: significantly bett

      Olga Petryna DrPetryna

      5 years ago
      #EULAR2020 #op0054 DISCOVER 1&2 rct results for Guselkumab in PsA w/ sacroiliitis: significantly better BaSDAI, improved spinal pain& ASDAS-CRP vs PBO suggestive of good clincial efficacy. No radiographic data @RheumNow https://t.co/MeXV08hcBU
      RT @DrPetryna: #EULAR2020 #op0051 presence of Structural Enthrseal Lesions (SEL) in PSO associated w/higher risk of prog

      Olga Petryna DrPetryna

      5 years ago
      #EULAR2020 #op0051 presence of Structural Enthrseal Lesions (SEL) in PSO associated w/higher risk of progression to PsA: 37.5%If SEL present vs 3.4% no SEL/no arthalgia& 15.2% no SEL/+arthralgia. Highest risk in PSO w/SEL+arthralgia at 42.8% @RheumNow https://t.co/7knYXeap7l
      RT @DrPetryna: How do you approach your PsA patients with suboptimal response to MTX in moderate doses?

      Olga Petryna DrPetryna

      5 years ago
      How do you approach your PsA patients with suboptimal response to MTX in moderate doses?
      RT @DrPetryna: #EULAR2020 #op0050 RCT ph4 results: in inadequately controlled PsA addition of ADA results in better outc

      Olga Petryna DrPetryna

      5 years ago
      #EULAR2020 #op0050 RCT ph4 results: in inadequately controlled PsA addition of ADA results in better outcomes in terms MDA, ACR20, PASI75, HAQ-DI&LEI as opposed to MTX dose escalation @RheumNow https://t.co/iMgCkRawCl
      ×